

Long Non-Coding RNAs Emerging as Potential Epigenetic Biomarkers for Tobacco and/or Alcohol-Induced Head and Neck Cancer

Shilpi Gupta^{1,2,*}, Prabhat Kumar², Jayant Maini³, Mausumi Bharadwaj¹

¹National Institute of Cancer Prevention and Research (ICMR), I-7, Sector-39, Noida-201301, India.

²Stem Cell and Cancer Research Lab, Amity Institute of Molecular Medicine & Stem Cell Research (AIMMSCR), Amity University Uttar Pradesh, Sector-125, Noida-201313, India.

³Dr. B. R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi-110007, India.

Abstract

Head and Neck cancer (HNC) is one of the most prevalent and lethal cancer globally. The incidence of tobacco-induced HNC is gradually increasing in low and middle income countries. Among the various causative factors associated with HNCs, tobacco and alcohol play synergistic effect and are frequently associated with the risk of HNC. Tobacco-induced HNCs show distinct genetic and epigenetic alterations leading to different clinical outcomes in comparison to HPV-infected HNCs. Tobacco-induced HNCs are often associated with tumor aggressiveness, poor prognosis and low or nil prevalence of HPV infection. Apart from carcinogenic effects of these causative factors (use of tobacco products, alcohol intake and HPV or EBV infections), recent studies show that exposure to these factors alter/disrupt the regulation of non-coding RNAs including the long non-coding RNAs (lncRNAs). Altered lncRNA regulation is brought about by signalling networks that regulate cellular differentiation, apoptosis, angiogenesis and inflammatory pathways which play key functions in the genesis of different cancers including HNCs. There are numbers of studies supporting the emerging role of lncRNAs in development of HNC; however, reports connecting lncRNAs expression and addiction habits in HNC are still preliminary and sparse. Therefore, identification and characterization of lncRNAs that are differentially expressed upon exposure to risk-factors can serve as unique therapeutic targets and potential biomarker(s) for effective treatment of HNC subtypes. In this short review, we briefly reviewed the emerging role of lncRNAs in tobacco and alcohol induced HNCs.

Corresponding author: Shilpi Gupta, Molecular Genetics and Biochemistry Lab, National Institute of Cancer Prevention and Research (ICMR), I-7, Sector - 39, NOIDA, Uttar Pradesh - 201301, INDIA, Mob: +918447207927

Keywords: HNC, non-coding RNAs, Long non-coding RNAs, HPV, Biomarker, Tobacco Smoking.

Received: Jul 17, 2019

Accepted: Aug 05, 2019

Published: Aug 07 2019

Editor: Anil Tombak, Mersin University Medical Faculty, Turkey.

Background

Head and neck cancer (HNC) represents a major public health problem globally. The incidence of tobacco-related HNC is increasing in low and middle income countries. Worldwide, HNCs accounts for ~80,7051 new cases and ~41,8323 deaths in 2018 [1]. HNCs originate from the upper head and neck region, including the lip, oral cavity, oropharynx, hypopharynx, nasopharynx, and larynx etc. Majority ($\geq 90\%$) of HNCs result from chewing tobacco, smoking cigarette/bidi as well as due to alcohol intake [2, 3]. Chewing Tobacco along-with betel, areca nut and slaked lime is more common in India and Asian countries. Tobacco smoke exerts inflammatory and suppressive effects on immune cells, alters mucosal immunity and promotes autoimmunity, resulting in HNCs. In the last few years, high-risk-human papillomaviruses (HR-HPVs) infection has become an independent risk factor for HNCs. HR-HPV infected HNCs show high variability across populations and geographic regions, mainly in Asian countries where the use of tobacco products is a regular part of the social life and tradition. Tobacco-induced HNCs show distinct genetic, epigenetic alterations, which can often be correlated with clinical outcome of HNC patients than HPV-infected HNCs. Tobacco-associated HNCs are often associated with aggressive metastasis, worst prognosis and low or nil of HPV prevalence. Association of different life style factors with HNC leads to heterogeneities and genetic/epigenetic changes. These genetic and epigenetic variations further effect outcome of the disease.

Even with the advances in the diagnosis and treatment methods, the 5-year survival (45%-50%) of HNC patients has not improved significantly over the last decade [4]. Therefore, prevention of postoperative recurrence and improvement of patient survival poses a major challenge in HNC diagnosis and treatment. To date, there is no significant potential molecular marker for development of effective targeted molecular therapies to treat HNC patients [5]. It seems, it is essential to investigate and identify therapeutic biomarkers based on risk-factors association for HNC patients. A number reports have illustrated that numerous non-coding RNAs (ncRNAs) can act as oncogenes and tumor suppressor genes playing key

regulatory roles in the disease development and pathophysiology of various cancers. In the several dysregulated ncRNAs in HNCs, long noncoding RNAs (lncRNAs) (>200 -nts in length) are a focus of current research providing suitable approaches for clinical treatment of HNCs. Recent evidences discovered that the lncRNAs can also serve as therapeutic targets at transcriptional, post-transcriptional and epigenetic levels [6, 7].

Tobacco and / or Alcohol Associated Head and Neck Cancers

Tobacco smoking and alcohol consumption are the strongest risk-factors for head and neck carcinogenesis around the world and is the major public health problem in Asian countries. Worldwide, more than 1.1 billion people smoke tobacco. But the incidence of tobacco smoking is high and is ever-increasing in low or middle-income countries like India [8]. Despite the fact that use of tobacco and alcohol annually kills more than seven million people, these products are legally sold by manufacturers in all over the world. As per the recent Global Adult Tobacco Survey India Report (2016-2017), more than 199 million smokeless tobacco users are living in India [9]. These lifestyle factors play a significant role in the aetiology of HNCs [10]. Globally, ~90% of HNCs are associated with avoidable well-known lifestyle factors such as tobacco chewing/smoking and alcohol drinking [11-19]. Regardless of the fact that majority of research studies on HNCs and other diseases are primarily focused on the use of alcohol and tobacco as well-established classical factors, their rates of consumption in many countries specially in low and middle income countries remain high, requiring a better understanding of the mechanisms in HNCs that are exposed to these risk-factors [20]. In addition to the carcinogenic effects of tobacco, alcohol, and their metabolites, studies have demonstrated that tobacco products along-with other life style factors (virus/bacterial infections and poor oral hygiene) can directly damage DNA, inducing DNA repair activity. Defective DNA repair can influence and modulate different genetic and epigenetic signalling pathways which effect transcriptional activation, DNA methylation, histone modifications, as well as the altered expression of

noncoding RNAs (miRNAs, PIWI-RNAs and LncRNAs etc.), which play critical roles in the genesis of different cancers including HNCs [14-16] [18].

Noncoding RNAs

Majority of the human genome is transcribed (ENCODE Consortium) and the 20,000 protein-coding genes represent only ~2% of the total genome, whereas about 98% is transcribed into RNA that does not code for protein. These non-protein coding RNA molecules comprise of functional RNA molecules [21, 22] which are categorized into housekeeping RNAs and regulatory RNAs [23]. The housekeeping RNAs are constitutively transcribed and includes ribosomal (rRNA), transfer (tRNA), small nuclear (snRNA), and small nucleolar RNAs (snoRNAs). The regulatory group of ncRNAs on the other hand are divided into two groups, one that are shorter than 200 nucleotides in length (small ncRNAs) and the ones that greater than 200 nucleotides (long ncRNAs). ncRNA molecules are represented by microRNAs (miRNAs), small interfering RNAs (siRNAs), and PIWI-interacting RNAs (piRNAs), circular RNAs (circRNAs), tRNA-derived small RNAs (tsRNAs) and long ncRNAs (lncRNAs) (Figure 1).

Overview of LncRNAs

Long non-coding RNAs are a highly diverse group of regulatory ncRNAs with respect to characteristics, localization and modes of action [24]. LncRNAs are ubiquitously transcribed in the human genome and are emerging as essential players regulating genomic imprinting, shaping chromosome conformation and allosterically regulating enzymatic activity. On the basis of their functions and regulation, lncRNAs are categorised into 3 types, (i) non-functional lncRNAs that are likely to be the result of transcriptional noise, (ii) lncRNAs for which the act of transcription alone is sufficient for their function but the transcript itself is not necessary and (iii) functional lncRNAs that can act in *cis* and/or in *trans* [25]. lncRNAs with a length of >200 nts, are localized in the nucleus. In the nucleus, they modulate transcription by sequestering transcription factors (TFs) or chromatin-modifying enzyme complexes and thus, regulating biological function. The altered expression of lncRNAs is documented as a new hallmark feature in variety of cancers including HNCs [26]. Furthermore, disrupted

expression of lncRNAs in HNC cells is associated with different stages of cancer and cancer progression (Figure 2).

Emerging Role of LncRNAs in Tobacco and/or Alcohol-Induced HNCs

LncRNAs, may act as oncogenic and tumor-suppressive thereby modulating clinical outcome of HNC patients. There are few reports that have found a link between tobacco smoking/alcohol consumption and altered expression of lncRNAs. These lncRNAs regulate molecular processes such cellular differentiation, apoptosis, angiogenesis, proliferation and inflammatory pathways which in turn lead to carcinogenesis [27]. The studies on the association between lncRNAs and addiction habits in head and neck cancer are still preliminary and sparse [28, 29].

In a study, Yu and co-workers (2016) demonstrated altered role of lncRNAs in alcohol induced HNC. The authors found the altered expression of lnc-PSD4-1 and lnc-NETO1-1 in alcohol and acetaldehyde induced HNCs [30]. In a recent study, expression profiling analysis of lncRNAs showed that 9 out of 11 analysed, were significantly dysregulated in tobacco chewer/smoker HNC patients. Further, altered regulation of linc-RoR ceRNA was observed in undifferentiated tumors which altered treatment response [31]. The altered expression level of HOTAIR (HOX transcript antisense RNA) is associated with many types of cancers including oncogenesis, metastasis and poor prognosis in HNC. HOTAIR is emerged as a potential biomarker for HNC diagnosis and prognosis [7] [32-34]. It is reported that polymorphisms could affect the expression of HOTAIR. The rs874945 polymorphism is located in the intron of HOTAIR gene. Recently, rs4759314 polymorphism present in the first intron of HOTAIR, contributes to an increased risk of HNC and serves as a potential biomarker [35]. Loss of expression of LINC01133 was found in oesophageal cancer tissues and cell lines indicating that it may have an anti-tumor effect in the early grades of oesophageal cancers. Interestingly, LINC01133 expression is markedly lower in patients who were regular drinker and serves as a possible poor prognostic marker and drug target for oesophageal cancers patients [36]. Further, alcohol intake has been associated with reduced




Figure 1. Different types of RNA molecules




Figure 2. Dysregulated expression of LncRNAs in head and neck cancer

expression of AC012456.4 in oral cancer patients [37]. rs11160608 polymorphism in MEG3 was significantly associated with alcohol-induced oral cancer patients and thus, might play an essential role in oral cancer pathogenesis [38].

LncRNA as Potential Therapeutic Targets

LncRNA expression is altered in various types of cancer. A number of lncRNAs play major roles in HNC metastasis based on their subcellular localization [39]. Most of these lncRNAs are located in nucleus and function in chromatin modifications and transcriptional regulation, examples include HOTAIR, MALAT1. On the other hand, lncRNAs such as FOXCUT, CCAT1, LIN00312 and NKILA (Nuclear Factor-kB interacting lncRNA) are localized in the cytoplasm and function as regulator/modulators of mRNA stability, translational controls and protein stability [39].

The above mentioned studies provide evidence for lncRNA as potential therapeutic targets. A number of techniques are available, that target lncRNAs. These have been reviewed by Arun et al., 2018 and include RNAi, antisense oligonucleotides (ASO), CRISPR/Cas, RNA blocking oligonucleotides and small-molecule modulators. RNAi as a therapeutic technique is challenged due to the complexity of *in-vivo* experiments as well as lack of proper delivery methods. Advancements in ASO chemistry has led to the development of Locked Nucleic Acids (LNA) and S-constrained ethyl (cEt) modifications, which have considerably improved potency and pharmacokinetics profiles [40]. Subcutaneously delivered ASO targeting Malat1 in luminal B breast cancer mouse model led to reduction (80%) in metastasis [41]. MALAT1 ASO is now being used in many types of metastatic cancers as a potential therapy [42]. The engineered CRISPR/Cas13 technique can be used to knockdown the lncRNAs [43]. This technique is engineered for mammalian RNA binding and knockdown [43]. Small molecule inhibitors may be utilized to target secondary or tertiary structures for lncRNAs, although this technique is still in its infancy [44].

Concluding Remarks

Globally, tobacco smoking/chewing, alcoholism and infection with oncogenic HPV infection are the substantial causative-factors for HNCs. The incidence of

tobacco-induced HNCs is increasing in Asian countries such as India, Srilanka, Pakistan and Bangladesh. Due to the intra-oral heterogeneities, differential risk-factors association and diverse etiology of HNCs, it is of great importance to identify novel molecular biomarkers for different subtypes of HNCs which may help to improve the disease outcome and patient survival. Recent discovery of new classes of long non-coding RNAs adds to an amazing complexity of RNA-mediated regulation involved in nearly all biological processes. It is imperative to crack the oncogenic/tumor suppressive function of lncRNAs in HNCs with its association with different risk-factors. Thus, proving them to be of great importance in diagnosis, prognosis and treatment of HNC. A curated collection of deregulated lncRNAs in different subtypes of HNC is essential to systematically understand the mechanisms and role of lncRNAs. The mechanism of interaction between lncRNAs and association of specific risk-factors is poorly understood and is still in the initial stage, this poses an obstacle to diagnosis and treatment of different subtypes of HNC. Continuous intensive research with better understanding about specific lncRNA signatures in HNCs associated with differential risk-factors holds great promise to be applied as a prognosticator of HNC and a novel therapeutic target to inhibit HNC metastasis, which will significantly improve HNC patient's survival rate.

Financial Support & Sponsorship

None.

Competing Interests

The authors have declared that no competing interests exist.

Acknowledgments

We sincerely thank all authors for their valuable inputs and carefully reading the article.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68:394-424.
2. Johnson NW. [Aetiology and risk factors for oral cancer, with special reference to tobacco and alcohol use]. *Magy Onkol.* 2001;45:115-22.

3. Warnakulasuriya S, Cain N. Screening for oral cancer: contributing to the debate. *J Investig Clin Dent*. 2011;2:2-9.
4. Bourhis J, Guigay J, Temam S, Pignon JP. Chemo-radiotherapy in head and neck cancer. *Ann Oncol*. 2006;17 Suppl 10:x39-41.
5. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. *Lancet*. 2008;371:1695-709.
6. Dykes IM, Emanuelli C. Transcriptional and Post-transcriptional Gene Regulation by Long Non-coding RNA. *Genomics Proteomics Bioinformatics*. 2017;15:177-86.
7. Li D, Feng J, Wu T, Wang Y, Sun Y, Ren J, et al. Long intergenic noncoding RNA HOTAIR is overexpressed and regulates PTEN methylation in laryngeal squamous cell carcinoma. *Am J Pathol*. 2012;182:64-70.
8. Mackay J, Eriksen M, Eriksen MP. The tobacco atlas: World Health Organization; 2002.
9. Saha I, Paul B. War against tobacco: Where do we stand? *Indian journal of public health*. 2018;62:55.
10. Humans IWGotEoCRt, World Health O, International Agency for Research on C. Tobacco smoke and involuntary smoking: Iarc; 2004.
11. Coglianò VJ, Baan R, Straif K. Updating IARC's carcinogenicity assessment of benzene. *Am J Ind Med*. 2011;54:165-7.
12. Coglianò VJ, Baan R, Straif K, Grosse Y, Lauby-Secretan B, El Ghissassi F, et al. Preventable exposures associated with human cancers. *J Natl Cancer Inst*. 2011;103:1827-39.
13. Elrefaey S, Massaro MA, Chiocca S, Chiesa F, Ansarin M. HPV in oropharyngeal cancer: the basics to know in clinical practice. *Acta Otorhinolaryngol Ital*. 2015;34:299-309.
14. Gupta S, Kumar P, Das BC. HPV: Molecular pathways and targets. *Curr Probl Cancer*. 2018;42:161-74.
15. Gupta S, Kumar P, Kaur H, Sharma N, Saluja D, Bharti AC, et al. Constitutive activation and overexpression of NF-kappaB/c-Rel in conjunction with p50 contribute to aggressive tongue tumorigenesis. *Oncotarget*. 2018;9:33011-29.
16. Gupta S, Kumar P, Kaur H, Sharma N, Saluja D, Bharti AC, et al. Selective participation of c-Jun with Fra-2/c-Fos promotes aggressive tumor phenotypes and poor prognosis in tongue cancer. *Sci Rep*. 2015;5:16811.
17. Gupta S, Kumar P, Maini J, Das BC, Bhardwaj M. PIWI-Interacting RNAs in Oral Cancer: Paradigm Shift in Prognosis and Diagnosis. *J Cancer Sci Ther*. 2019;11:086-90.
18. Gupta S, Kumar P, Maini J, Kaur H, Das BC. Epigenetic Biomarkers in Head and Neck Cancer. *Journal of Cancer Genetics and Biomarkers*. 2018;1:41.
19. Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. *Cancer Epidemiol Biomarkers Prev*. 2009;18:541-50.
20. Beynon RA, Lang S, Schimansky S, Penfold CM, Waylen A, Thomas SJ, et al. Tobacco smoking and alcohol drinking at diagnosis of head and neck cancer and all-cause mortality: Results from head and neck 5000, a prospective observational cohort of people with head and neck cancer. *Int J Cancer*. 2018;143:1114-27.
21. Osielska MA, Jagodzinski PP. Long non-coding RNA as potential biomarkers in non-small-cell lung cancer: What do we know so far? *Biomed Pharmacother*. 2018;101:322-33.
22. Ponting CP, Belgard TG. Transcribed dark matter: meaning or myth? *Hum Mol Genet*. 2010;19:R162-8.
23. Palazzo AF, Lee ES. Non-coding RNA: what is functional and what is junk? *Front Genet*. 2015;6:2.
24. Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. *Genetics*. 2013;193:651-69.
25. Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. *Nat Rev Genet*. 2015;17:47-62.
26. Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. *Cancer Discov*. 2011;1:391-407.

27. Soares do Amaral N, Cruz EMN, de Melo Maia B, Malagoli Rocha R. Noncoding RNA Profiles in Tobacco- and Alcohol-Associated Diseases. *Genes (Basel)*. 2016;8.
28. Pentenero M, Bowers L, Jayasinghe R, Cheong SC, Farah CS, Kerr AR, et al. World Workshop on Oral Medicine VII: Functional pathways involving differentially expressed lncRNAs in oral squamous cell carcinoma. *Oral Dis*. 2019;25 Suppl 1:79-87.
29. Pentenero M, Bowers LM, Jayasinghe R, Yap T, Cheong SC, Kerr AR, et al. World Workshop on Oral Medicine VII: Clinical evidence of differential expression of lncRNAs in oral squamous cell carcinoma: A scoping review. *Oral Dis*. 2019;25 Suppl 1:88-101.
30. Yu V, Singh P, Rahimy E, Zheng H, Kuo SZ, Kim E, et al. RNA-seq analysis identifies key long non-coding RNAs connected to the pathogenesis of alcohol-associated head and neck squamous cell carcinoma. *Oncol Lett*. 2016;12:2846-53.
31. Arunkumar G, Deva Magendhra Rao AK, Manikandan M, Arun K, Vinothkumar V, Revathidevi S, et al. Expression profiling of long non-coding RNA identifies linc-RoR as a prognostic biomarker in oral cancer. *Tumour Biol*. 2017;39:1010428317698366.
32. Lee M, Kim HJ, Kim SW, Park SA, Chun KH, Cho NH, et al. The long non-coding RNA HOTAIR increases tumour growth and invasion in cervical cancer by targeting the Notch pathway. *Oncotarget*. 2016;7:44558-71.
33. Nie Y, Liu X, Qu S, Song E, Zou H, Gong C. Long non-coding RNA HOTAIR is an independent prognostic marker for nasopharyngeal carcinoma progression and survival. *Cancer Sci*. 2013;104:458-64.
34. Zhou X, Chen J, Tang W. The molecular mechanism of HOTAIR in tumorigenesis, metastasis, and drug resistance. *Acta Biochim Biophys Sin (Shanghai)*. 2014;46:1011-5.
35. Wu B, Liu J, Wang B, Liao X, Cui Z, Ding N. Association on polymorphisms in lncRNA HOTAIR and susceptibility to HNSCC in Chinese population. *Eur Rev Med Pharmacol Sci*. 2018;22:702-6.
36. Yang XZ, He QJ, Cheng TT, Chi J, Lei ZY, Tang Z, et al. Predictive Value of LINC01133 for Unfavorable Prognosis was Impacted by Alcohol in Esophageal Squamous Cell Carcinoma. *Cell Physiol Biochem*. 2018;48:251-62.
37. Hu X, Qiu Z, Zeng J, Xiao T, Ke Z, Lyu H. A novel long non-coding RNA, AC012456.4, as a valuable and independent prognostic biomarker of survival in oral squamous cell carcinoma. *PeerJ*. 2018;6:e5307.
38. Hou Y, Zhang B, Miao L, Ji Y, Yu Y, Zhu L, et al. Association of long non-coding RNA MEG3 polymorphisms with oral squamous cell carcinoma risk. *Oral Dis*. 2019;25:1318-24.
39. Luo X, Qiu Y, Jiang Y, Chen F, Jiang L, Zhou Y, et al. Long non-coding RNA implicated in the invasion and metastasis of head and neck cancer: possible function and mechanisms. *Mol Cancer*. 2018;17:14.
40. Arunkumar G, Anand S, Raksha P, Dhamodharan S, Prasanna Srinivasa Rao H, Subbiah S, et al. lncRNA OIP5-AS1 is overexpressed in undifferentiated oral tumors and integrated analysis identifies as a downstream effector of stemness-associated transcription factors. *Sci Rep*. 2018;8:7018.
41. Arun G, Diermeier S, Akerman M, Chang KC, Wilkinson JE, Hearn S, et al. Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. *Genes Dev*. 2015;30:34-51.
42. Mendell JT. Targeting a Long Noncoding RNA in Breast Cancer. *N Engl J Med*. 2016;374:2287-9.
43. Abudayyeh OO, Gootenberg JS, Essletzbichler P, Han S, Joung J, Belanto JJ, et al. RNA targeting with CRISPR-Cas13. *Nature*. 2017;550:280-4.
44. Howe JA, Wang H, Fischmann TO, Balibar CJ, Xiao L, Galgoci AM, et al. Selective small-molecule inhibition of an RNA structural element. *Nature*. 2015;526:672-7.